Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 3/2007

01-03-2007 | Original Article

Probiotic Effects on 5-Fluorouracil-Induced Mucositis Assessed by the Sucrose Breath Test in Rats

Authors: Chad A. Mauger, Ross N. Butler, Mark S. Geier, Katie L. Tooley, Gordon S. Howarth

Published in: Digestive Diseases and Sciences | Issue 3/2007

Login to get access

Abstract

The sucrose breath test (SBT) was employed to noninvasively assess the efficacy of probiotics in 5-fluorouracil (5-FU)-induced intestinal mucositis. Dark Agouti rats were allocated to 5 groups (n=10): 5-FU+L. fermentum BR11, 5-FU+L. rhamnosus GG, 5-FU+B. lactis BB12, 5-FU+skim milk (SM), and saline+SM. Probiotics were administered by oral gavage for 10 days. Mucositis was induced on day 7 by intraperitoneal injection of 5-FU (150 mg/kg) or vehicle (saline). Rats were sacrificed 72 h after 5-FU injection. The SBT measured breath 13CO2 (expressed as percentage cumulative dose at 90 min; %CD90) on days 0, 7, and 10. %CD90 was significantly lower in 5-FU-treated controls compared with that in saline-treated controls on day 10. 5-FU caused an 83% reduction in sucrase and a 510% increase in MPO activity. The SBT detected damage induced by 5-FU and is a simple, noninvasive indicator of small bowel injury. The probiotics assessed offered no protection from mucositis at the dose tested.
Literature
1.
Sonis ST, Eilers JP, Epstein JB, LeVeque FG, Liggett Jr WH, Mulagha MT, Peterson DE, Rose AH, Schubert MM, Spijkervet FK, et al. (1999) Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 85:2103–2113PubMedCrossRef
2.
Pico J-L, Avila-Garavito A, Naccache P (1998) Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3:446–451PubMed
3.
Khan SA, Wingard JR (2001) Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr 31–36
4.
5.
Clarke J, Butler R, Howarth G, Read L, Regester G (2002) Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 38:478–485PubMedCrossRef
6.
Sonis ST (2004) A biological approach to mucositis. J Support Oncol 2:21–32; discussion 35–36PubMed
7.
Freytes CO, Ratanatharathorn V, Taylor C, Abboud C, Chesser N, Restrepo A, Arango J, Odenheimer D (2004) Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Cancer Res 10:8318–8324PubMedCrossRef
8.
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598PubMedCrossRef
9.
Howarth GS (2003) Insulin-like growth factor-I and the gastrointestinal system: therapeutic indications and safety implications. J Nutr 133:2109–2112PubMed
10.
Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC (1996) Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 126:2519–2530PubMed
11.
Harsha WT, Kalandarova E, McNutt P, Irwin R, Noel J (2006) Nutritional supplementation with transforming growth factor-beta, glutamine, and short chain fatty acids minimizes methotrexate-induced injury. J Pediatr Gastroenterol Nutr 42:53–58PubMedCrossRef
12.
O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, et al. (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551PubMedCrossRef
13.
Isolauri E (2001) Probiotics in human disease. Am J Clin Nutr 73:1142S–1146SPubMed
14.
Mombelli B, Gismondo MR (2000) The use of probiotics in medical practice. Int J Antimicrob Agents 16:531–536PubMedCrossRef
15.
Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580–591PubMedCrossRef
16.
Park SY, Ji GE, Ko YT, Jung HK, Ustunol Z, Pestka JJ (1999) Potentiation of hydrogen peroxide, nitric oxide, and cytokine production in RAW 264.7 macrophage cells exposed to human and commercial isolates. Int J Food Microbiol 46:231–241PubMedCrossRef
17.
Bezkorovainy A (2001) Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr 73:S399–S405
18.
Ruiz PA, Hoffmann M, Szency S, Blaut M, Haller D (2005) Innate mechanisms of Bifidobacterium lactis to activate transient pro-inflammatory host response in intestinal epithelial cells after the colonization of germ-free rats. Immunology 115:441–450PubMedCrossRef
19.
Kullisaar T, Zilmer M, Mikelsaar M, Vihalemm T, Annuk H, Kairane C, Kilk A (2002) Two antioxidative lactobacilli strains as promising probiotics. Int J Food Microbiol 72:215–224PubMedCrossRef
20.
Hung J, Cooper D, Turner MS, Walsh T, Giffard PM (2003) Cystine up take prevents production of hydrogen peroxide by Lactobacillus fermentum BR11. FEMS Microbiol Lett 69:5855–5863
21.
Rush CM, Hafner LM, Timms P (1994) Genetic modification of a vaginal strain of Lactobacillus fermentum and its maintenance within the reproductive tract after intravaginal administration. J Med Microbiol 41:272–278PubMedCrossRef
22.
Geier MS, Butler RN, Howarth GS (2005) Differential efficacy of probiotic species in amelioration of dextran sulphate sodium-induced colitis in rats. Gastroenterology 128:A603–A604
23.
Pelton NS, Tivey DR, Howarth GS, Davidson GP, Butler RN (2004) A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol 39:1015–1016PubMedCrossRef
24.
Semenza G, Dahlqvist A (1985) Disaccharides of small-intestinal mucosa. J Pediatr Gastroenterol Nutr 4:857–867PubMedCrossRef
25.
Clarke JM, Pelton NC, Bajka BH, Howarth GS, Read LC, Butler RN (2006) Use of the (13)c-sucrose breath test to assess chemotherapy-induced small intestinal mucositis in the rat. Cancer Biol Ther 5:34–38PubMedCrossRef
26.
McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI (1998) Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 34:484–490PubMedCrossRef
27.
Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Bllard FJ (1991) Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. J Endocrinol 128:97–105PubMedCrossRef
28.
Xian CJ, Howarth GS, Cool JC, Foster BK (2004) Effects of acute 5-fluorouracil chemotherapy and insulin-like growth factor-I pretreament on growth plate cartilage and metaphyseal bone in rats. Bone 35:739–749PubMedCrossRef
29.
Cool JC, Dyer JL, Xian CJ, Butler RN, Geier MS, Howarth GS (2005) Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res 15:72–82PubMedCrossRef
30.
31.
Krawisz JE, Sharon P, Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344–1350PubMed
32.
Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA, Howarth GS (2005) Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol 204:687–692PubMedCrossRef
33.
Howarth GS, Xian CJ, Read LC (2000) Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-I for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors 18:119–133PubMedCrossRef
34.
Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, Campieri M, Morgenstern S, Rachmilewitz D (2002) Variable response to probiotics in two models of experimental colitis in rats. Inflammatory Bowel Dis 8:399–406CrossRef
35.
Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, Grenther WB, Sartor RB (2003) Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52:370–376PubMedCrossRef
36.
Di Stefano M, Miceli E, Armellini E, Missanelli A, Corazza GR (2004) Probiotics and functional abdominal bloating. J Clin Gastroenterol 38:S102–S103PubMedCrossRef
37.
Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22:387–394PubMedCrossRef
38.
Hawrelak JA, Whitten DL, Myers SP (2005) Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion 72:51–56PubMedCrossRef
39.
Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R (2005) Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy—a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 21:1263–1272PubMedCrossRef
40.
Tooley K, Howarth G, Lymn K, Lawrence A, Butler R (2006) Oral ingestion of Streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer Biol Ther 5(6):593–600
Metadata
Title
Probiotic Effects on 5-Fluorouracil-Induced Mucositis Assessed by the Sucrose Breath Test in Rats
Authors
Chad A. Mauger
Ross N. Butler
Mark S. Geier
Katie L. Tooley
Gordon S. Howarth
Publication date
01-03-2007
Published in
Digestive Diseases and Sciences / Issue 3/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9464-y

Other articles of this Issue 3/2007

Digestive Diseases and Sciences 3/2007 Go to the issue

Original Paper

The Influence of Gallbladder Function on the Symptomatology in Gallstone Patients, and the Outcome after Cholecystectomy or Expectancy

Original Paper

Deoxycholate-Induced Colitis is Markedly Attenuated in Nos2 Knockout Mice in Association with Modulation of Gene Expression Profiles

Review Paper

The Role of Probiotics in Inflammatory Bowel Disease

Original ARTICLE

The Multiple Faces of Glucagon-Like Peptide-1—Obesity, Appetite, and Stress: What Is Next? A Review

Original Article

Growth Rate of Locally Recurrent Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization: Comparing the Growth Rate of Locally Recurrent Tumor with That of Primary Hepatocellular Carcinoma

Original Paper

Incidence of Gastrointestinal Stromal Tumor: A Retrospective Study Based on Immunohistochemical and Mutational Analyses
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits